tiprankstipranks
Towa Pharmaceutical Co Ltd (JP:4553)
:4553
Japanese Market
4553
Towa Pharmaceutical Co
RESEARCH TOOLSreports
Want to see JP:4553 full AI Analyst Report?

Towa Pharmaceutical Co (4553) Ratios

0 Followers

Towa Pharmaceutical Co Ratios

JP:4553's free cash flow for Q1 2026 was ¥0.36. For the 2026 fiscal year, JP:4553's free cash flow was decreased by ¥ and operating cash flow was ¥0.08. See a summary of the company’s cash flow.
Ratios
TTM
Mar 26Mar 26Mar 25Mar 24
Liquidity Ratios
Current Ratio
 ― 2.81 2.76 2.72 2.33
Quick Ratio
 ― 1.58 1.49 1.46 1.15
Cash Ratio
 ― 0.52 0.47 0.37 0.31
Solvency Ratio
 ― 0.13 0.09 0.12 0.09
Operating Cash Flow Ratio
 ― 0.27 0.31 0.10 0.03
Short-Term Operating Cash Flow Coverage
 ― 1.03 1.00 0.62 0.23
Net Current Asset Value
¥ ―¥ -51.89B¥ -29.84B¥ -57.04B¥ -51.46B
Leverage Ratios
Debt-to-Assets Ratio
 ― 0.49 0.48 0.47 0.47
Debt-to-Equity Ratio
 ― 1.35 1.27 1.30 1.26
Debt-to-Capital Ratio
 ― 0.57 0.56 0.56 0.56
Long-Term Debt-to-Capital Ratio
 ― 0.53 0.51 0.55 0.52
Financial Leverage Ratio
 ― 2.74 2.67 2.76 2.71
Debt Service Coverage Ratio
 ― 1.48 1.16 1.92 1.92
Interest Coverage Ratio
 ― 14.29 10.22 18.63 8.68
Debt to Market Cap
 ― 1.65 1.08 1.45 1.73
Interest Debt Per Share
 ― 4.73K 4.65K 4.13K 3.53K
Net Debt to EBITDA
 ― 4.28 3.95 4.86 5.92
Profitability Margins
Gross Profit Margin
―36.49%36.21%35.70%34.81%
EBIT Margin
―8.95%8.44%7.74%2.75%
EBITDA Margin
―16.70%16.78%15.59%12.04%
Operating Profit Margin
―8.95%8.44%7.74%2.64%
Pretax Profit Margin
―10.14%4.81%10.73%2.20%
Net Profit Margin
―7.31%1.92%7.10%1.05%
Continuous Operations Profit Margin
―7.31%1.92%7.10%1.05%
Net Income Per EBT
―72.11%39.88%66.12%47.80%
EBT Per EBIT
―113.28%56.98%138.60%83.51%
Return on Assets (ROA)
―4.03%1.10%3.76%0.59%
Return on Equity (ROE)
―11.06%2.95%10.37%1.61%
Return on Capital Employed (ROCE)
―6.07%6.11%5.03%1.88%
Return on Invested Capital (ROIC)
―4.12%2.25%3.21%0.87%
Return on Tangible Assets
―4.47%1.17%4.26%0.69%
Earnings Yield
―14.40%2.66%11.61%2.36%
Efficiency Ratios
Receivables Turnover
 ― 3.62 3.70 3.18 3.84
Payables Turnover
 ― 5.49 5.24 5.56 4.35
Inventory Turnover
 ― 1.52 1.41 1.45 1.47
Fixed Asset Turnover
 ― 1.54 1.60 1.48 1.64
Asset Turnover
 ― 0.55 0.58 0.53 0.56
Working Capital Turnover Ratio
 ― 1.75 1.66 1.88 2.67
Cash Conversion Cycle
 ― 273.95 286.99 300.80 260.32
Days of Sales Outstanding
 ― 100.72 98.68 114.75 95.05
Days of Inventory Outstanding
 ― 239.74 258.01 251.73 249.13
Days of Payables Outstanding
 ― 66.51 69.70 65.68 83.87
Operating Cycle
 ― 340.46 356.69 366.48 344.19
Cash Flow Ratios
Operating Cash Flow Per Share
 ― 475.39 618.12 166.84 51.68
Free Cash Flow Per Share
 ― -108.38 165.60 -632.11 -567.33
CapEx Per Share
 ― 583.77 452.53 798.95 619.01
Free Cash Flow to Operating Cash Flow
 ― -0.23 0.27 -3.79 -10.98
Dividend Paid and CapEx Coverage Ratio
 ― 0.74 1.16 0.19 0.08
Capital Expenditure Coverage Ratio
 ― 0.81 1.37 0.21 0.08
Operating Cash Flow Coverage Ratio
 ― 0.10 0.13 0.04 0.01
Operating Cash Flow to Sales Ratio
 ― 0.09 0.11 0.04 0.01
Free Cash Flow Yield
―-4.05%4.13%-22.34%-29.94%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
 ― 6.95 37.55 8.61 42.38
Price-to-Sales (P/S) Ratio
 ― 0.51 0.72 0.61 0.45
Price-to-Book (P/B) Ratio
 ― 0.77 1.11 0.89 0.68
Price-to-Free Cash Flow (P/FCF) Ratio
 ― -24.72 24.19 -4.48 -3.34
Price-to-Operating Cash Flow Ratio
 ― 5.64 6.48 16.96 36.66
Price-to-Earnings Growth (PEG) Ratio
 ― 0.40 -0.52 0.01 -0.49
Price-to-Fair Value
 ― 0.77 1.11 0.89 0.68
Enterprise Value Multiple
 ― 7.32 8.24 8.78 9.63
Enterprise Value
 ― 317.39B 378.59B 312.00B 242.08B
EV to EBITDA
 ― 7.32 8.24 8.78 9.63
EV to Sales
 ― 1.22 1.38 1.37 1.16
EV to Free Cash Flow
 ― -59.49 46.44 -10.03 -8.67
EV to Operating Cash Flow
 ― 13.56 12.44 37.99 95.16
Tangible Book Value Per Share
 ― 2.56K 3.08K 2.14K 1.71K
Shareholders’ Equity Per Share
 ― 3.49K 3.62K 3.17K 2.78K
Tax and Other Ratios
Effective Tax Rate
 ― 0.28 0.60 0.34 0.52
Revenue Per Share
 ― 5.27K 5.56K 4.63K 4.24K
Net Income Per Share
 ― 385.70 106.65 328.58 44.72
Tax Burden
 ― 0.72 0.40 0.66 0.48
Interest Burden
 ― 1.13 0.57 1.39 0.80
Research & Development to Revenue
 ― 0.06 0.00 0.06 0.07
SG&A to Revenue
 ― 0.21 0.28 0.00 0.00
Stock-Based Compensation to Revenue
 ― 0.00 0.00 0.00 0.00
Income Quality
 ― 1.23 5.80 0.51 0.55
Currency in JPY